NOVEL CAR T THAT TARGETS MUC1*NOT FULL-LENGTH MUC1 FOR TREATMENT OF SOLID TUMOR CANCERS

被引：2
|
作者：
Bamdad, C. [1 ]
Stewart, A. K. [1 ]
Smagghe, B. J. [1 ]
Huang, P. [1 ]
Glennie, N. D. [1 ]
Deary, L. T. [1 ]
机构：
[1] Minerva Biotechnol, Waltham, MA USA
来源：
CYTOTHERAPY | 2018年 / 20卷 / 05期
关键词：
D O I：
10.1016/j.jcyt.2018.02.007
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
1
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [31] MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization
    Son, Hye-Youn
    Jeong, Hwan-Kyu
    Apostolopoulos, Vasso
    Kim, Chul-Woo
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2022, 36
  • [32] Inhibiting MUC1 a/b chain interaction mediates cytotoxicity of cells expressing MUC1: The MUC1 dyad oncoprotein as a functional target
    Karmely, M.
    Rubinstein, D. B.
    Pichinuk, E.
    Ziv, R.
    Benhar, I.
    Feng, N.
    Wreschner, D. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] What makes MUC1 a tumor antigen?
    Karsten, U
    von Mensdorff-Pouilly, S
    Goletz, S
    TUMOR BIOLOGY, 2005, 26 (04) : 217 - 220
  • [34] MUC1-ARF-A Novel MUC1 Protein That Resides in the Nucleus and Is Expressed by Alternate Reading Frame Translation of MUC1 mRNA
    Chalick, Michael
    Jacobi, Oded
    Pichinuk, Edward
    Garbar, Christian
    Bensussan, Armand
    Meeker, Alan
    Ziv, Ravit
    Zehavi, Tania
    Smorodinsky, Nechama I.
    Hilkens, John
    Hanisch, Franz-Georg
    Rubinstein, Daniel B.
    Wreschner, Daniel H.
    PLOS ONE, 2016, 11 (10):
  • [35] MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue
    Schut, IC
    Waterfall, PM
    Ross, M
    O'Sullivan, C
    Miller, WR
    Habib, FK
    Bayne, CW
    BJU INTERNATIONAL, 2003, 91 (03) : 278 - 283
  • [36] Local Effects of Regulatory T Cells in MUC1 Transgenic Mice Potentiate Growth of MUC1 Expressing Tumor Cells In Vivo
    Sugiura, Daisuke
    Denda-Nagai, Kaori
    Takashima, Mitsuyo
    Murakami, Ryuichi
    Nagai, Shigenori
    Takeda, Kazuyoshi
    Irimura, Tatsuro
    PLOS ONE, 2012, 7 (09):
  • [37] MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice
    Lakshminarayanan, Vani
    Supekar, Nitin T.
    Wei, Jie
    McCurry, Dustin B.
    Dueck, Amylou C.
    Kosiorek, Heidi E.
    Trivedi, Priyanka P.
    Bradley, Judy M.
    Madsen, Cathy S.
    Pathangey, Latha B.
    Hoelzinger, Dominique B.
    Wolfert, Margreet A.
    Boons, Geert-Jan
    Cohen, Peter A.
    Gendler, Sandra J.
    PLOS ONE, 2016, 11 (01):
  • [38] Tumour immunotherapy against MUC1 expressing tumours using mannan MUC1
    Apostolopoulos, V
    Pietersz, GA
    Acres, B
    Osinski, C
    Thynne, G
    Xing, PX
    Karanikas, V
    Vaughan, HA
    Hwang, L
    Popovski, V
    Lees, C
    Ong, CS
    McKenzie, IFC
    BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, 1996, : 315 - 320
  • [39] Functional targeting of the MUC1 oncogene in human cancers
    Kufe, Donald W.
    CANCER BIOLOGY & THERAPY, 2009, 8 (13) : 1197 - 1203
  • [40] The decision between tolerance and immunity to MUC1 is based on the differences in MUC1 glycosylation
    Ryan, Sean O.
    Wong, Man Yan
    Turner, Michael S.
    Vlad, Anda M.
    Finn, Olivera J.
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S265 - S266
12345